Printer Friendly

COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF ETHOSUXIMIDE SYRUP, 250MG/5ML

 CANTON, Mass., Aug. 3 /PRNewswire/ -- Copley Pharmaceutical, Inc. (NASDAQ: CPLY) announced today the FDA approval of Ethosuximide Syrup, 250 mg/5 mL.
 Ethosuximide Syrup is the generic equivalent of Zarontin(R) Syrup (Parke-Davis). It is indicated for the control of absence (petit mal) epilepsy.
 Copley Pharmaceutical, Inc. develops, manufactures and markets a broad range of off-patent prescription and over-the-counter pharmaceutical products in a variety of dosage forms and strengths, including extended-release products. The company markets its products to distributors, retail chains, wholesalers, hospitals, government agencies and managed care entities.
 -0- 8/3/93
 /CONTACT: Dr. Mark Hirsh, executive vice president - marketing and business development for Copley Pharmaceuticals, 800-325-6111 or 617-821-6111/
 (CPLY)


CO: Copley Pharmaceuticals, Inc. ST: Massachusetts IN: MTC SU: PDT

CM-DJ -- NE013 -- 8951 08/03/93 13:46 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 3, 1993
Words:130
Previous Article:SUMITOMO METALS INDUSTRIES CONVERTS LTX DEBENTURE
Next Article:GENERAL INSTRUMENT CORPORATION IN $250 MILLION PACT TO SUPPLY DIGICIPHER DIGITAL COMPRESSION TECHNOLOGY TO PRIMESTAR
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters